SCHEMBL22013506

SCHEMBL22013506

CCC(=O)c1cccc(-c2ccc(Cl)o2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.43
ALDH1A1 P00352 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
PTGS1 P23219 3/20 0.40
SOS1 Q07889 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
PRMT1 Q99873 1/20 0.38
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
KEAP1 Q14145 1/20 0.38
ATM Q13315 1/20 0.38
S1PR4 O95977 1/20 0.38
NQO2 P16083 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17742698 0.83 PRKDC (0.49) POLBTP53HPGDL3MBTL1ALDH1A1
SCHEMBL17773160 0.79 ALDH1A1 (0.46) POLBTP53HPGDL3MBTL1ALDH1A1
SCHEMBL7536493 0.75 MAPT (0.56) HPGDL3MBTL1SMN1; SMN2MAPTERCC5
SCHEMBL6005391 0.74 L3MBTL1 (0.69) HPGDL3MBTL1TDP1SMN1; SMN2MAPT
SCHEMBL6603881 0.74 MAPT (0.50) L3MBTL1SMN1; SMN2MAPTERCC5FEN1
SCHEMBL9848178 0.73 CYP1A2 (0.50) POLBTP53HPGDL3MBTL1ALDH1A1
SCHEMBL10389972 0.73 SMN1; SMN2 (0.54) POLBHPGDL3MBTL1ALDH1A1TDP1
SCHEMBL13078374 0.73 KMO (0.63) L3MBTL1SMN1; SMN2MAPTERCC5FEN1
SCHEMBL116338 0.72 ERCC5 (0.61) HPGDALDH1A1SMN1; SMN2MAPTERCC5
SCHEMBL16178565 0.70 SMN1; SMN2 (0.79) HPGDL3MBTL1ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662183-B2 Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662183-B2 Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same SREBF1, SREBF2, BPTF POLB 3134/4885TP53 1223/4885HPGD 2422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.